Cytosorbents.
company
- Reports this week
- 1
- Active events
- 1
- Connections
- 20
What's happening
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Cytosorbents this week
News at the entities that move Cytosorbents most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Cytosorbents
-
AstraZeneca OperationalAstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Moves Cytosorbents
-
Nasdaq StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Cytosorbents
-
New York City Shared contextJoint entities are driving a high volume of General Obligation bond issuance in New York City.Moves Cytosorbents
-
Automated Insights Mentioned togetherZacks provided analyst estimates for Cognizant's earnings, which Automated Insights then used to generate a story.Moves Cytosorbents
-
Middle East Shared contextAuthorities are investigating an incident at a base in Fairford, with possible links to Iran and Russia.Moves Cytosorbents
Connections
The 10 strongest of 20, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Phillip Chan Structural
Phillip Chan holds the formal role of Chief Executive Officer of Cytosorbents.
-
FDA Structural
FDA regulates Cytosorbents' drug submissions, issuing denials and providing market authorization guidance.
-
Phil Chan Structural
Phil Chan serves as the CEO of Cytosorbents, establishing a leadership and functional dependency.
-
Tom Shannon Structural
Cytosorbents appointed Tom Shannon as VP of Marketing to lead marketing strategy for DrugSorb-ATR.
-
AstraZeneca Operational
Cytosorbents' drug product is clinically used alongside AstraZeneca's Brilinta in patients.
-
S. Lee Operational
S. Lee provides financial forecasts and analysis regarding Cytosorbents' earnings.
-
Nasdaq Structural
Cytosorbents must maintain minimum bid price requirements to remain listed on the Nasdaq exchange.
-
New York City Shared context
Cytosorbents holds an investor conference within New York City.
Show all 10 connections
-
Automated Insights Mentioned together
Automated Insights utilizes Cytosorbents' company data to generate financial stories and earnings snapshots.
-
Middle East Shared context
The evidence discusses the general business outlook of the Middle East but does not mention Cytosorbents.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
1 eventJune 2026
4 events- The FDA upheld the De Novo denial for DrugSorb-ATR, a product of CytoSorbents. Phillip Chan serves as the company's CEO.
- Cytosorbents is conducting research and commercialization in the US and Germany.
- Sales growth for Cytosorbents was driven by Germany on August 14, 2025.
- CytoSorbents will present at a conference on September 5, 2025.